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Patient-funded trials (PFTs) are gaining traction as ameans of accelerating clinical translation. However, such
trials sidestepmechanisms that promote rigor, relevance, efficiency, and fairness. We recommend that fund-
ing bodies or research institutions establish mechanisms for merit review of patient-funded trials, and we
offer some basic criteria for evaluating PFT protocols.Introduction
A new funding model that claims to
empower patients and expand the re-
sources available for cutting-edge re-
search is picking up steam and garnering
particular attention in cell-based interven-
tion research. Studies funded by patients
have been conducted for conditions
ranging from Parkinson’s disease (Fikes,
2013) to Multiple Sclerosis (Cree et al.,
2010) to ALS (Sipp, 2012), and they have
begun to attract mainstream media atten-
tion. Models of patient funding can take
many forms, from crowd-funding cam-
paigns to support academic researchers,
to studies in which participants pay for ac-
cess to investigational interventions in for-
profit clinics. In addition, the U.S. FDA
(U.S. Department of Health and Human
Services) permits drug companies to
recover costs fromsubjects for trial partic-
ipation in certain circumstances. Our
focus is on patient-funded trials (PFTs), a
term we use to refer to studies funded
directly by patients seeking to enroll in tri-
als as participants.
Supporters of PFTs hope for better-
informed patient engagement in clinical
research and greater opportunities to pur-
sue research lines that lack public funding
or industry support. They contend that
worries about patient autonomy and the
potential for exploitation are overblown
and manageable via existing oversight
and review mechanisms (Vayena and Ta-
sioulas, 2013a, 2013b). Concerns about
conflictsof interest betweenpatient payers
and sound trial design have been dis-
missed as no different from those encoun-
tered in industry-sponsored research (Mor-
reim, 1991).
Whatever progress this model might
bring to cutting-edge research, it is sub-ject to several liabilities that have not
yet been adequately considered. PFTs
change relationships between research
stakeholders—patients, researchers, and
sponsors in particular—in ways that un-
dermine the ability of oversight systems
to protect patients, ensure the production
of reliablemedical evidence, and preserve
confidence in the research enterprise it-
self. Without adequate corrective mea-
sures, this reconfiguration of research
relationships leaves the PFT model prone
to inefficiencies, including exploitation by
those seeking to use the cachet of cut-
ting-edge science to market unproven,
ineffective, and perhaps even dangerous
interventions to patients desperate for a
cure.
The Vulnerabilities of PFTs
Although research stakeholders share a
common interest in promoting health
through the production of reliable medi-
cal evidence, they are also each moti-
vated by strong parochial interests.
Drug companies are driven by commer-
cial considerations, patients seek access
to promising new treatments, and scien-
tists hope to advance their careers
through successful research and publica-
tion. Left unchecked, these interests can
threaten the ability of research to
advance biomedical progress. The goal
of oversight and regulation is to align
these myriad interests with the social
objectives of advancing science and
improving health. Existing oversight
mechanisms promote this alignment by
focusing on the long-term interests of
traditional study sponsors and re-
searchers. They are not geared toward
aligning the near-term objectives of pa-
tient funders and PFT clinics with theCell Stem Cell 1broader goal of efficient and reliable
medical evidence production.
First, consider how existing oversight
mechanisms promote research effi-
ciency. Requirements for market access
attempt to align the profit motive of
private sponsors with the demands of
sound science. Sponsors must produce
adequate evidence regarding safety,
toxicity, and efficacy before submitting a
marketing application. Since trials are
expensive, sponsors generally prefer to
minimize the number and duration of
studies necessary to generate that evi-
dence. This provides an incentive to
conduct research quickly while mini-
mizing sample sizes and, therefore, pa-
tient exposure to unproven interventions.
In PFTs, patient sponsors are strongly
motivated by the short-term goal of ac-
cess to new interventions and the profit
motive shifts from the sponsor to PFT
clinics, which generate revenue directly
from the enrollment of participants.
Clinics offering PFTs often charge sub-
stantial fees for trial access; for example,
according to a recent report from The
Detroit News, Novastem, the exclusive
distributor inMexico of stem cell products
of the U.S. company Stemedica, con-
ducts research at Clinica Santa Clarita
where it costs U.S. $30,000 to participate
in a trial of the use of neural stem cells for
the treatment of stroke-related brain dam-
age. This funding model effectively re-
verses incentives to minimize sample
size and encourages sponsors to enroll
large cohorts. In doing so, it also in-
creases patient exposure to the risks of
unproven interventions. And, because
clinic revenues derive directly from
research rather than a product’s commer-
cialization, the downstream desire for7, August 6, 2015 ª2015 Elsevier Inc. 135
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longer exerts pressure to quickly and effi-
ciently distinguish promising interventions
from ineffective or harmful ones. Instead,
trials are launched such as one recent
phase I/II study from the Ageless Regen-
erative Institute that plans to enroll 500
participants to test autologous adipose-
derived stromal cells on patient funders
for the treatment of erectile dysfunc-
tion—a sample size far greater than
typical early-phase explorations.
Second, consider how current systems
try to ensure that studies are founded on
solid scientific rationales and that patients
are not exposed to risks without first es-
tablishing the potential for the generation
of important data. Publicly funded studies
are screened via peer review. Although
imperfect, this mechanism uses the sci-
entific community’s standards of eviden-
tial support to weed out studies that lack
sufficient grounding before patients are
put at risk in a trial. Because industry
sponsors can only recoup research in-
vestments after licensure, they have
strong incentives to pursue platforms or
interventions that have the most compel-
ling evidential support.
As stated above, however, investiga-
tors pursuing PFTs can market their
investigative products directly to pa-
tients. The initiation of a trial doesn’t
depend on peer review committees or a
concern for downstream marketing
approval. Rather, the ‘‘gatekeepers’’ for
trial launch are patients, often with
debilitating or life-threatening diseases.
Although some such patients may have
the acumen and emotional reserve to
properly vet PFT clinics and review the
preclinical evidence, many will lack the
requisite knowledge or motivation to do
so. The result is the ability of unscrupu-
lous clinics to co-opt the ‘‘therapeutic
hope’’ (Hyun, 2013) of desperate patients
to sell them access to ‘‘trials’’ of inter-
ventions with little or no scientific foun-
dation. This may be of particular concern
in new stem cell modalities, where high-
profile media reports of ‘‘miracle cures’’
like the stem cell treatments that purport-
edly restored strength to Denver quarter-
back Peyton Manning’s throwing arm or
aided hockey legend Gordon Howe’s
post-stroke recovery are likely to breed
unrealistic expectations about the out-
comes associated with investigational
treatments.136 Cell Stem Cell 17, August 6, 2015 ª2015Third, consider how existing incentive
mechanisms promote the production of
high-quality evidence. The threat of
regulatory disapproval is leveraged to
encourage industry sponsors to utilize
‘‘gold standard’’ methodologies such as
blinding and randomization. Peer review
plays a similar function for publicly-
funded studies. Although these mecha-
nisms are imperfect, there is no compara-
ble means to encourage study quality in
the PFT model. Patient funders primarily
seeking access to new interventions are
unlikely to fund studies that might
randomize them to something other than
the investigational intervention, exclude
them based on eligibility criteria, or
involve burdensome research procedures
for monitoring effect. Indeed, many PFTs
utilize open-label and case series designs
(Baker, 2005), which are notoriously unre-
liable and in numerous instances have
suggested clinical utility that was later
decisively refuted in randomized trials. In
some instances, the research element in
PFTs is even presented as secondary to
treatment access. For instance, one clinic
(Arbitrage Medical) advertises that patient
funders are ‘‘strongly encourage[d]. to
participate in longitudinal patient data
collection to demonstrate. that these
therapies offer fundamental improve-
ment’’ in health status. The upshot is
that absent constraints on methodology,
the PFT model invites the production of
low-quality evidence.
Moreover, unless the shortcomings
canvassed here can be addressed, the
proliferation of PFTs could also create
liabilities that reach beyond this particular
funding model. If such trials recruit
large numbers of patients in areas that
compete with studies grounded in strong
scientific rationales, the net effect could
be to stymie rigorous evaluations of new
strategies in the very areas where they
are needed most. This is of particular
concern in rare diseases, which are also
the areas in which the PFT model may
be most attractive to investigators and
patients.
Finally, even if patient funders under-
stand and freely accept the risks associ-
ated with this funding model, high-profile
events occurring in one study can alter
beliefs and activities surrounding other,
related research (London et al., 2010). A
debacle involving patient injury, for
example, or even a string of negative find-Elsevier Inc.ings, can deter investment in what might
otherwise be a promising line of research.
This occurred in gene therapy after the
high-profile death of Jesse Gelsinger in
1999. This is a concern in PFTs, where pa-
tients’ desires for access to new treat-
ment options and dosages with directly
observable outcomesmay encourage un-
usually aggressive study designs, such as
rapid dose escalation or the early enroll-
ment of recent-onset patients.
Recommendations
Key aspirations of the patient-funded
model are to provide participants with
greater control while also enabling
research in areas that are currently un-
funded or under-funded. If PFTs are to
achieve these goals, policies must be de-
signed to align participant and investi-
gator interests with the imperatives of
socially valuable research. At a minimum,
this means that policies and mechanisms
are needed to encourage the use of
research methods that minimize bias,
promote the vetting of preclinical evi-
dence before the launching of PFTs, and
ensure that potential patient funders are
in a position to assess the scientific value
and rigor of the trials they might fund.
The creation of such mechanisms is
likely to be difficult in the absence of
centralized rule making and may require
coordinated efforts on the parts of multi-
ple parties. Ethics review might play a
role in this process, but it will likely be
insufficient for at least two reasons. First,
in countries such as the U.S., private
clinics may not always be required to sub-
mit protocols for ethical review, as when
they do not receive federal funds or pur-
sue Investigational New Drug applica-
tions. Second, ethics review committees
often have limited capacity as well as an
ambiguous mandate for vetting the pre-
clinical evidence and scientific quality of
the studies they review.
Instead, we suggest three broad direc-
tions for possible reform, with the recog-
nition that any such reforms would require
careful study and may be difficult to
implement. First, policy makers could
create a mechanism for providing scienti-
fic and ethical oversight of PFTs. This
could take many forms, some of the
more ambitious of which would require
large-scale policy changes. For example,
steps could be taken to empower public
research agencies—such as the NIH or
Cell Stem Cell
Forumthe California Institute of Regenerative
Medicine in the U.S.—to provide external
review and ethical oversight of PFTs. This
might be modeled loosely on the Recom-
binant DNA Advisory Committee’s public
reviews of novel gene transfer trials. In
the near-term, clinics offering PFTs
should establish credible and fully inde-
pendent scientific panels to review pre-
clinical data and methodological features
of proposed trials. For this approach to
successfully avoid the vulnerabilities
canvassed above, however, the estab-
lishment of mechanisms to ensure the
credibility and independence of such
panels would be crucial.
Second, to encourage the use of such
mechanisms in the absence of larger legal
or policy mandates, academic medical
centers, professional organizations, and
licensing boards should discourage their
members from participating in studies
not approved via such review. For
example, academic medical centers
could make credible, independent scien-
tific review of PFTs a requirement for
study approval. National and international
professional organizations could amend
codes of conduct to clearly signal that
such review is required to remain within
accepted professional norms, and
licensing boards can signal that it is a
requirement for acceptable professional
practice.
Finally, policy makers should consider
whether accreditation requirements for
health care facilities could be used to
encourage entities conducting PFTs to
utilize an appropriate mechanism for sci-
entific review and ethical oversight.
Although incomplete, these sugges-
tions attempt to balance the legitimate
goals of PFTs with the social mandate
to ensure that research is scientifically
sound, ethically conducted, and worthy
of continued support. Yet any suchincomplete approach has downsides.
First, without comprehensive policies
that apply to all researchers or health fa-
cilities, incremental reforms may shift
the demand for PFTs to those investiga-
tors and clinics without significant cre-
dentials to protect. This may not
eliminate dubious clinics, but with
mechanisms in place to clearly signal
which clinics are performing valuable
research and which are not, their im-
pacts might be minimized. Second,
merely reducing the number of dubious
PFTs may be insufficient to prevent the
stigma associated with PFTs that pro-
mote low-quality research or harbor un-
ethical researchers from spilling over
into public perceptions of legitimate
PFTs or the broader clinical research en-
terprise. Finally, even if the PFT market
could be more transparently segmented
into those studies that have markers of
scientific quality and those that do not,
ethical concerns about the latter market
would remain. In particular, limited
research resources absorbed by low-
quality studies impose opportunity costs
on legitimate research, and PFTs may
involve significant financial burdens for
participants and their families that go
unredeemed by the prospect of either
individual benefit or social value.
The goals of PFTs to empower pa-
tients, expand available research re-
sources, and accelerate the pace of
translation are worthy and important ob-
jectives. Because the current system
lacks regulations or incentives that
constructively channel the desires of pa-
tients, the ardor of investigators, and the
profit motives of host clinics, this funding
model harbors important liabilities for
both patients and the broader clinical
research enterprise. Building institutional
mechanisms to ensure that PFTs pro-
mote high scientific and ethical stan-Cell Stem Cell 1dards will help ensure that this new
model advances not only the interests
of patient payers, but of science and so-
ciety as well.WEB RESOURCES
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